Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talazoparib - Pfizer

X
Drug Profile

Talazoparib - Pfizer

Alternative Names: BMN-673; BMN-673ts; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate; TALZENNA

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEAD Therapeutics
  • Developer Astellas Pharma; Big Ten Cancer Research Consortium; BioGene Pharmaceutical; Brown University; Calithera Biosciences; Center Trials & Treatment; Dana-Farber Cancer Institute; Epizyme; LifeSpan; National Cancer Institute (USA); Peter MacCallum Cancer Centre; Pfizer; St. Jude Childrens Research Hospital; Stanford University; Translational Research In Oncology; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center; Zenith Epigenetics
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; HER2 negative breast cancer; Prostate cancer
  • Phase III Ovarian cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Phase I/II Acute myeloid leukaemia
  • No development reported Haematological malignancies; Myelodysplastic syndromes

Most Recent Events

  • 02 Apr 2024 Pfizer completes a phase-I clinical trial in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04134884)
  • 07 Mar 2024 Zenith Epigenetics in collaboration with Pfizer and Newsoara Biopharma terminates a phase II trial in Triple-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO), due to the results from an interim futility analysis (NCT03901469) (EudraCT2018-003906-26)
  • 25 Jan 2024 Efficacy data from the phase-III TALAPRO-2 trial in Prostate cancer presented at the ASCO Genitourinary Cancers Symposium (ASCO-GCS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top